|
|
Prepublished online as a Blood First Edition Paper on February 6, 2003; DOI 10.1182/blood-2002-04-1250.
 Previous Article | Table of Contents | Next Article 
Blood, 15 June 2003, Vol. 101, No. 12, pp. 4930-4936
NEOPLASIA
T-cell epitopes within the complementarity-determining and framework regions of the tumor-derived immunoglobulin heavy chain in multiple myeloma
Lotta Hansson,
Hodjattallah Rabbani,
Jan Fagerberg,
Anders Österborg, and
Håkan Mellstedt
From the Department of Hematology, Karolinska Hospital, Stockholm, Sweden; and the Department of Oncology (Radiumhemmet) and Cancer Centre Karolinska, Karolinska Hospital, Stockholm, Sweden.
The idiotypic structure of the monoclonal immunoglobulin (Ig) in multiple myeloma (MM) might be regarded as a tumor-specific antigen. The present study was designed to identify T-cell epitopes of the variable region of the Ig heavy chain (VH) in MM (n = 5) using bioinformatics and analyze the presence of naturally occurring T cells against idiotype-derived peptides. A large number of human-leukocyte-antigen (HLA)–binding (class I and II) peptides were identified. The frequency of predicted epitopes depended on the database used: 245 in bioinformatics and molecular analysis section (BIMAS) and 601 in SYFPEITHI. Most of the peptides displayed a binding half-life or score in the low or intermediate affinity range. The majority of the predicted peptides were complementarity-determining region (CDR)–rather than framework region (FR)–derived (52%-60% vs 40%-48%, respectively). Most of the predicted peptides were confined to the CDR2-FR3-CDR3 "geographic" region of the Ig-VH region (70%), and significantly fewer peptides were found within the flanking (FR1-CDR1-FR2 and FR4) regions (P < .01). There were 8– to 10–amino acid (aa) long peptides corresponding to the CDRs and fitting to the actual HLA-A/B haplotypes that spontaneously recognized, albeit with a low magnitude, type I T cells (interferon  ), indicating an ongoing major histocompatibility complex (MHC) class I–restricted T-cell response. Most of those peptides had a low binding half-life (BIMAS) and a low/intermediate score (SYFPEITHI). Furthermore, 15- to 20-aa long CDR1-3–derived peptides also spontaneously recognized type I T cells, indicating the presence of MHC class II–restricted T cells as well. This study demonstrates that a large number of HLA-binding idiotypic peptides can be identified in patients with MM. Such peptides may spontaneously induce a type I MHC class I– as well as class II–restricted memory T-cell response.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
S. Cohen, J. Haimovich, and N. Hollander
Dendritic Cell-Based Therapeutic Vaccination against Myeloma: Vaccine Formulation Determines Efficacy against Light Chain Myeloma
J. Immunol.,
February 1, 2009;
182(3):
1667 - 1673.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. A. Richards, F. A. Chaves, F. R. Krafcik, D. J. Topham, C. A. Lazarski, and A. J. Sant
Direct Ex Vivo Analyses of HLA-DR1 Transgenic Mice Reveal an Exceptionally Broad Pattern of Immunodominance in the Primary HLA-DR1-Restricted CD4 T-Cell Response to Influenza Virus Hemagglutinin
J. Virol.,
July 15, 2007;
81(14):
7608 - 7619.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. v. Rhee
Idiotype Vaccination Strategies in Myeloma: How to Overcome a Dysfunctional Immune System
Clin. Cancer Res.,
March 1, 2007;
13(5):
1353 - 1355.
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Hansson, A. O. Abdalla, A. Moshfegh, A. Choudhury, H. Rabbani, B. Nilsson, A. Osterborg, and H. Mellstedt
Long-term Idiotype Vaccination Combined with Interleukin-12 (IL-12), or IL-12 and Granulocyte Macrophage Colony-Stimulating Factor, in Early-Stage Multiple Myeloma Patients
Clin. Cancer Res.,
March 1, 2007;
13(5):
1503 - 1510.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Bot, D. Smith, B. Phillips, S. Bot, C. Bona, and H. Zaghouani
Immunologic Control of Tumors by In Vivo Fc{gamma} Receptor-Targeted Antigen Loading in Conjunction with Double-Stranded RNA-Mediated Immune Modulation
J. Immunol.,
February 1, 2006;
176(3):
1363 - 1374.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Choi, M. Witzens, M. Bucur, M. Feuerer, N. Sommerfeldt, A. Trojan, A. Ho, V. Schirrmacher, H. Goldschmidt, and P. Beckhove
Enrichment of functional CD8 memory T cells specific for MUC1 in bone marrow of patients with multiple myeloma
Blood,
March 1, 2005;
105(5):
2132 - 2134.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y.-D. Wang, W.-Y. F. Sin, G.-B. Xu, H.-H. Yang, T.-y. Wong, X.-W. Pang, X.-Y. He, H.-G. Zhang, J. N. L. Ng, C.-S. S. Cheng, et al.
T-Cell Epitopes in Severe Acute Respiratory Syndrome (SARS) Coronavirus Spike Protein Elicit a Specific T-Cell Immune Response in Patients Who Recover from SARS
J. Virol.,
June 1, 2004;
78(11):
5612 - 5618.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
